Published: 2 April 2023
Author(s): Yusaku Kajihara
Issue: July 2023
Section: Letter to the Editor

Vonoprazan is an oral potassium-competitive acid blocker that has a greater acid-inhibitory effect than proton pump inhibitors (PPIs). Many studies have shown that vonoprazan-based triple therapy had greater efficacy than PPI-based triple therapy for Helicobacter pylori eradication [1]. However, limited information is available on the risk factors for adverse events (AEs) in vonoprazan-besed triple therapy.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.